ProPhase Labs Inc. to Present First Quarter 2025 Financial Results on May 20, 2025
ProPhase Labs Inc. (NASDAQ: PRPH) has announced it will present its first quarter 2025 financial results in a virtual conference call on May 20, 2025, at 10:00 am EDT. The call, hosted by Renmark Financial, will feature CEO Ted Karkus providing updates on key initiatives, including:
- The planned sale of subsidiary Nebula Genomics
- Crown Medical Collections' initiative to recover tens of millions in accounts receivable
A press release with detailed results will be issued before the call. The company, a next-generation biotech, genomics and consumer products company, focuses on Whole Genome Sequencing solutions, diagnostic development including early esophageal cancer detection, and direct-to-consumer marketing for OTC dietary supplements.
ProPhase Labs Inc. (NASDAQ: PRPH) ha annunciato che presenterà i risultati finanziari del primo trimestre 2025 durante una conferenza virtuale il 20 maggio 2025 alle 10:00 EDT. La chiamata, organizzata da Renmark Financial, vedrà il CEO Ted Karkus fornire aggiornamenti su iniziative chiave, tra cui:
- La prevista vendita della controllata Nebula Genomics
- L'iniziativa di Crown Medical Collections per recuperare decine di milioni in crediti
Un comunicato stampa con i dettagli dei risultati sarà pubblicato prima della chiamata. L'azienda, una società biotecnologica di nuova generazione specializzata in genomica e prodotti per il consumatore, si concentra su soluzioni di sequenziamento dell'intero genoma, sviluppo diagnostico incluso il rilevamento precoce del cancro esofageo e marketing diretto al consumatore per integratori alimentari OTC.
ProPhase Labs Inc. (NASDAQ: PRPH) ha anunciado que presentará sus resultados financieros del primer trimestre de 2025 en una conferencia virtual el 20 de mayo de 2025 a las 10:00 am EDT. La llamada, organizada por Renmark Financial, contará con el CEO Ted Karkus, quien ofrecerá actualizaciones sobre iniciativas clave, incluyendo:
- La venta planificada de la subsidiaria Nebula Genomics
- La iniciativa de Crown Medical Collections para recuperar decenas de millones en cuentas por cobrar
Se emitirá un comunicado de prensa con detalles antes de la llamada. La compañía, una empresa biotecnológica de próxima generación, especializada en genómica y productos para consumidores, se enfoca en soluciones de secuenciación del genoma completo, desarrollo diagnóstico incluyendo la detección temprana del cáncer de esófago y marketing directo al consumidor para suplementos dietéticos OTC.
ProPhase Labs Inc. (NASDAQ: PRPH)는 2025년 1분기 재무 결과를 2025년 5월 20일 오전 10시 EDT에 가상 컨퍼런스 콜을 통해 발표할 예정이라고 밝혔습니다. Renmark Financial이 주최하는 이번 콜에서는 CEO Ted Karkus가 다음과 같은 주요 이니셔티브에 대한 업데이트를 제공할 예정입니다:
- 자회사 Nebula Genomics의 예정된 매각
- Crown Medical Collections의 수천만 달러에 달하는 미수금 회수 계획
상세한 결과가 담긴 보도자료는 콜 전에 배포될 예정입니다. 이 회사는 차세대 생명공학, 유전체학 및 소비자 제품 회사로, 전체 게놈 시퀀싱 솔루션, 초기 식도암 진단을 포함한 진단 개발, OTC 건강보조식품의 직접 소비자 마케팅에 주력하고 있습니다.
ProPhase Labs Inc. (NASDAQ : PRPH) a annoncé qu'elle présenterait ses résultats financiers du premier trimestre 2025 lors d'une conférence téléphonique virtuelle le 20 mai 2025 à 10h00 EDT. L'appel, organisé par Renmark Financial, sera animé par le PDG Ted Karkus, qui donnera des mises à jour sur les initiatives clés, notamment :
- La vente prévue de la filiale Nebula Genomics
- L'initiative de Crown Medical Collections visant à récupérer des dizaines de millions en comptes clients
Un communiqué de presse détaillant les résultats sera publié avant l'appel. L'entreprise, une société de biotechnologie, de génomique et de produits grand public de nouvelle génération, se concentre sur les solutions de séquençage du génome complet, le développement de diagnostics incluant la détection précoce du cancer de l'œsophage, ainsi que le marketing direct aux consommateurs pour les compléments alimentaires en vente libre.
ProPhase Labs Inc. (NASDAQ: PRPH) hat angekündigt, dass es seine Finanzergebnisse für das erste Quartal 2025 in einer virtuellen Telefonkonferenz am 20. Mai 2025 um 10:00 Uhr EDT präsentieren wird. Die von Renmark Financial veranstaltete Telefonkonferenz wird vom CEO Ted Karkus geleitet, der Updates zu wichtigen Initiativen geben wird, darunter:
- Der geplante Verkauf der Tochtergesellschaft Nebula Genomics
- Die Initiative von Crown Medical Collections zur Rückgewinnung von mehreren zehn Millionen an Forderungen
Eine Pressemitteilung mit detaillierten Ergebnissen wird vor der Telefonkonferenz veröffentlicht. Das Unternehmen, ein Biotech-, Genomik- und Konsumgüterunternehmen der nächsten Generation, konzentriert sich auf Lösungen zur Ganzgenomsequenzierung, die Entwicklung von Diagnostika einschließlich der Früherkennung von Speiseröhrenkrebs sowie das Direktmarketing für rezeptfreie Nahrungsergänzungsmittel.
- None.
- None.
GARDEN CITY, NY, May 13, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics and consumer products company, announced today that they will be presenting first quarter 2025 financial results on a virtual conference call hosted by Renmark Financial on May 20, 2025, at 10:00 am EDT. Ted Karkus, CEO, looks forward to providing shareholders with an update on several positive activities, including the initiative to sell the Company’s wholly owned subsidiary, Nebula Genomics, and the Crown Medical Collections initiative to collect tens of millions of dollars in accounts receivable.
A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event.
Investors interested in participating in this live event will need to register using the link below. After the event, a replay will be available on The Company’s investor website.
REGISTER HERE: https://www.renmarkfinancial.com/events/first-quarter-2025-results-virtual-conference-call-nasdaq-prph-b--whRs2Li
- To ensure smooth connectivity, please access this link using the latest version of Google Chrome.
About ProPhase Labs Inc.
ProPhase Labs Inc. (Nasdaq: PRPH) (“ProPhase”) is a next-generation biotech, genomics and consumer products company. Our mission is to build a healthier world through bold innovation and actionable insight. We’re revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, groundbreaking diagnostic development – such as our potentially life-saving test for the early detection of esophageal cancer – and a world class direct-to-consumer marketing platform for cutting edge OTC dietary supplements. We develop, manufacture, and commercialize health and wellness solutions to enable people to live their best lives. We are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach. ProPhase Labs’ valuable subsidiaries, their synergies, and significant growth underscore our potential for long-term value. www.ProPhaseLabs.com
Media Relations and Institutional Investor Contact:
ProPhase Labs, Inc.
investorrelations@prophaselabs.com
Retail Investor Relations Contact:
Renmark Financial Communications Inc.
John Boidman: jboidman@renmarkfinancial.com
Tel.: (416) 644-2020 or (212) 812-7680
www.renmarkfinancial.com
FAQ
When will PRPH release its Q1 2025 earnings?
What key updates will be discussed in ProPhase Labs' Q1 2025 earnings call?
How can investors participate in PRPH's Q1 2025 earnings call?
What are ProPhase Labs' main business segments?
